Nā Mea Hoʻohui Peptide ADC ʻElua-Uku: Hoʻohuihui, Nā Nīnau Hōʻikeʻike a me ka Handoff

Pane wikiwiki

Peptide and linker chemistry can constrain a dual-payload ADC program, alongside antibody production, payload supply, huikau, analytics and formulation. D…

He aha ka mea e hoʻololi i ka ʻenehana ke lawe ka ADC i ʻelua mau uku ma mua o hoʻokahi

M Peptides Mea Hoolako Hoʻohui hou i nā peptides ʻAʻole i manaʻo ʻia ʻelua hoʻoili kūʻokoʻa. I loko o ka hoʻolālā pālua-payload nā ʻāpana controllable kahi e hoʻopili ai kēlā me kēia lāʻau, pehea i hoʻokuʻu ʻia ai kēlā me kēia, ka awelika huina DAR a me ka A:B uku uku lākiō, no laila DAR_total = DAR_A + AKA_B, me ka A:Lakiō B ma ke ʻano he ʻokoʻa hiki ke mālama ʻia (ʻO Wen et al., mAbs, 2025). Hiki i ke kūkulu ke hoʻopaʻa i ka DAR a pau a he ʻano mole ʻokoʻa.

Nā Mea Hoʻohui Peptide ADC ʻElua-Uku: Hoʻohuihui, Nā Nīnau Hōʻikeʻike a me ka Handoff

Hoʻopuka ʻia nā hoʻonohonoho DAR uku pālua ʻelua Hoʻopuka ʻia nā hoʻonohonoho DAR uku pālua ʻelua, e like me ka manao mai ke kumu i oleloia. Hoʻopuka ʻia nā hoʻonohonoho DAR uku pālua ʻelua. ʻikepili pae pae: anti-CD30 8+8 16; SPARC2 8+8 16; MMAE+DM1 2.83+5.25 8.1; KH815 7.5; anti-HER2 4+2 6; JSKN021 4+2 6; MMAF+SN38 2.4+1.7 4.1.Puna: Nā lāʻau lapaʻau 19:860 (PMC13305441) 2026. Hoʻopuka ʻia nā hoʻonohonoho DAR uku pālua ʻelua anti-CD30 8+8 16 SPARC2 8+8 16 MMAE+DM12.83+5.25 8.1 KH815 7.5 anti-HER2 4+2 6 JSKN021 4+2 6 MMAF+SN382.4+1.7 4.1 Puna: Nā lāʻau lapaʻau 19:860 (PMC13305441) (2026)

ʻO ka hoʻolālā hoʻohui e lawe i kēlā kaumaha. ʻO nā loulou lālā me nā lima hoʻihoʻi orthogonal, no ka laʻana hoʻokahi lima thiol-reactive a me hoʻokahi lima kaomi-reactive, e ʻae i ka hoʻopili pū ʻana o nā ukana pili ʻole kemika (ʻO Wen et al., mAbs, 2025). Hōʻike nā kūkulu i paʻi ʻia i ka laulā o ka holo ʻana o ka hoʻolālā: a 2026 ka nānā ʻana o nā kūkulu haʻahaʻa ʻelua e hoʻopaʻa i nā pālua DAR mai ka haʻahaʻa kiʻekiʻe anti-CD30 MMAE/MMAF conjugates a hiki i ka haʻahaʻa haʻahaʻa MMAF/SN38 pairs (Nā lāʻau lapaʻau 19:860, 2026).

Pono ka ratio ma kona iho. A 2025 ka nānā 'ana i nā hō'ike ho'ohālike like 'elua-payload conjugation a 4+2 Kūkulu ʻia ʻo MMAE/MMAF me ka ʻoi aku ka maikaʻi o ka DAR6 MMAE ADC a me ka DAR4 hoʻokele hoʻokahi ADC., i nā hiʻohiʻona preclinical mai kahi hui e kūʻai aku ana i kahi paepae pālua-uku (ʻO Wen et al., mAbs, 2025). E mālama i kēlā me he kuhiakau hoʻolālā, ʻaʻole kahi ratio i hoʻopaʻa ʻia. ʻO ka hopena kūpono no ka ADC linker-payload chemistry ʻo ia ka peptide a me ka linker pono e kuhikuhi ʻia i kēlā me kēia lima., ʻaʻole i kēlā me kēia mole.

Nā Mea Hoʻohui Peptide ADC ʻElua-Uku: Hoʻohuihui, Nā Nīnau Hōʻikeʻike a me ka Handoff

Kahi e kūpono ai ka peptide, a no ke aha he mea paʻakikī ka linker-peptide

ʻO kēlā ʻōlelo kikoʻī no kēlā me kēia lima ma ka peptide, pono e hoʻohui ʻia i kahi kikoʻī ma mua o ka hiki ʻana o kekahi conjugation a ma laila kahi i ʻike ʻia ai nā ʻano hana hemahema.. ʻO ka ʻohana linker Val-Cit-PABC e pili ana i ka lysosomal enzyme cleavage a ukali ʻia e kahi spacer PABC self-immolative e hoʻokuʻu i ka uku e 1,4/1,6-elimination. (ʻO Guo et al., Nā palena i ka Immunology, 2026). Hoʻokaʻawale ʻia ka loulou GGFG tetrapeptide i hoʻohana ʻia i nā conjugates DXd e ke ala lysosomal like., no laila ke hana nei ke kaʻina peptide i ka hoʻokuʻu kemika, ʻaʻole wale ke kaawale.

ʻO nā hale hoʻolālā pālua-payload e hoʻoikaika i ka peptide. Hoʻokumu ka hale hoʻolālā hoʻohui multipayload a SPARC i nā modules mai kahi dipeptide VA linker me kahi polysarcosine-PAB self-immolative spacer, hoʻākoakoa ʻia e CuAAC a hoʻopili ʻia me ka orthogonally ma ka pūnaewele VA (ʻO Sun et al., Kemika Bioconjugate, 2025). ʻO ia kahi peptide me kahi kiko lālā i wehewehe ʻia, kahi mea hoʻokuʻu i wehewehe ʻia a me kahi kahua hoʻopili lua i wehewehe ʻia, pau i ka papa hookahi.

ʻO kēlā mau hiʻohiʻona ʻo ia nā pilikia synthesis. He kaʻina e lawe ana i ʻelua cysteinees pale ʻokoʻa, ʻO kahi kikoo hydrophobic payload-e pili ana a me kahi spacer self-immolative e hoʻopaʻa i nā paʻakikī paʻakikī maʻamau.: epimerization i kēlā me kēia hui, ka hoʻokumu ʻana o ka aspartimide kahi i ʻike ʻia ai nā kumu Asp-Gly, a me ka hoʻohui ʻana ma luna o ka resin ma o ka holo hydrophobic. Hōʻike ka Seattle Genetics orthogonal cysteine ​​approach i ka kemika i hiki ke loaʻa ma kahi protein i pelu ʻia (Levengood et al., Angew Chem Int Ed, 2017); inā paha e hiki i ka mea hoʻolako hāʻawi ke hoʻokō iā ia ma kāu pālākiō he nīnau kaʻawale, a ʻo ka mea nāna e hoʻoholo i kāu laina manawa.

Pehea e hoʻopili ʻia ai ka mea hoʻopili-peptide ʻelua-lima a pale ʻia?

Hiki i ka pale Orthogonal ke hana i ka hana i ka wā e ʻae ai kēlā me kēia reagent a me waena i ka pae aʻe. ʻO ka mea i haʻi ʻia 2017 He laʻana mōʻaukala ke kemika, ʻaʻole wale ke ala hiki ke hana; koho i kahi kaʻina scalable a hoʻomalu i nā koena reagent, me nā metala inā pili.

ʻO ka koho ke kiko. ʻO ka pale ʻana i hoʻokahi cysteine ​​ma ke ʻano he disulfide hiki ke hoʻemi ʻia a ʻo kekahi ʻē aʻe e like me Acm e hoʻokomo i nā uku uku ma hope o kekahi. (Levengood et al., Angew Chem Int Ed, 2017). Paʻa ka Acm i ka TCEP akā hoʻoneʻe ʻia e ka aqueous mercury acetate, ʻo ia ka mea e hiki ai ke kauoha (Levengood et al., Angew Chem Int Ed, 2017). Hōʻike ka pepa like i ke kūkulu ʻana ma 16 huina laau lapaau, mokuahana 8+8, ma 98% monomer me ka paʻa antigen i paʻa, ʻo ia ke kumu o ke kauoha deprotection he kaohi hoʻolālā ma mua o kahi kikoʻī hoʻomaʻemaʻe.

ʻIke maʻamau ʻo Sortase A i kahi kumu LPXTG, he laʻana o LPETG, a hiki ke hoʻopili i kahi nucleophile oligoglycine kūpono. ʻO ke kumu a me nā koi substrate e pili ana i ka enzyme a me ke kūkulu ʻana.

Pehea mākou e hoʻohana ai i kēia ma MOL Changes, ka mea hoʻopuka o kēia alakaʻi. Hoʻopili mākou i nā peptides maʻamau i kāu kaʻina i kuhikuhi ʻia, a hiki i 200 nā ʻakika amino, no laila hiki ke kūkulu ʻia kahi linker-peptide i ka kikoʻī per-lima āu i hoʻonohonoho ai ma mua o ka conjugation. ʻAʻole mākou e hana i ka pale cysteine ​​orthogonal a i ʻole kahi hana conjugation, a ʻaʻole mākou e hoʻopiʻi i nā mea hoʻopili pālua uku; ka papa hana pale, ʻO ke ala conjugation a me ka mana DAR e waiho ʻia iā ʻoe e hoʻolālā a hōʻoia.

Pehea e kaohi ai ka conjugation kiko'ī pūnaewele i ka hoʻolālā peptide?

Hoʻoholo ke ala conjugation i ka mea e mālama i kāu peptide e lawe a pono e mālama ʻia. Hāʻawi ka Stochastic lysine a i ʻole interchain-cysteine ​​conjugation i nā DAR heterogenous, ʻoiai ʻo ka cysteine ​​i hana ʻia, ʻO nā ala amino non-canonical a me glycan-remodelling ala e hāʻawi i ka mana DAR paʻa, me ka hoʻoponopono hou ʻana o glycan ma Fc Asn297 me ka hoʻohana ʻana i kahi kahua mamao mamao e hoʻopilikia liʻiliʻi i ka paʻa antigen. (Ocana et al., ʻO ka hoʻololi ʻana i ka hōʻailona a me ka hoʻomaʻamaʻa ʻia, 2026). Unuhi ʻia kēlā me kēia ala i kahi kikoʻī peptide ʻokoʻa.

ʻO nā helu paipu i paʻi ʻia ka lā- a pili i ka wehewehe a ʻokoʻa ma waena o nā loiloi. ʻAʻole hōʻike ke komo ʻana i kahi noiʻi lapaʻau mua Mea Hoʻolako Polypeptide o ka pomaikai lapaau. ʻAʻole hoʻokumu kēia ʻatikala i kahi helu piha o kēia manawa a i ʻole ka hopena maikaʻi a i ʻole ka hopena palekana.

ʻAʻole ʻae nā kumu i ka nui o ka bioconjugation kikoʻī pūnaewele e kūʻai ai. ʻekahi 2026 Hōʻike maopopo ʻia ka loiloi ʻaʻole maopopo i ka nui o ka hoʻomaikaʻi ʻana i ka homogeneity i hāʻawi i nā hopena lapaʻau, e ʻike ana i kēlā trastuzumab emtansine, ʻO trastuzumab deruxtecan a me sacituzumab govitecan hiki ke hoʻohana i ka conjugation maʻamau a hōʻike i ka pono lapaʻau. (Kumari et al., Nā maʻi maʻi maʻi, 2026). Hoʻonohonoho kekahi i nā ala kikoʻī pūnaewele e like me ka hiki ʻana i ka mana DAR paʻa i ka wā e mālama ana i ke ʻano antibody a me ka pilina antigen. (Ocana et al., ʻO ka hoʻololi ʻana i ka hōʻailona a me ka hoʻomaʻamaʻa ʻia, 2026). Hiki i nā mea ʻelua ke ʻoiaʻiʻo: ʻO ka mana ʻoi aku ka maikaʻi, a ʻaʻole hōʻoia ʻia kāna unuhi lapaʻau. ʻAʻohe kumu e hoʻohālikelike i ka mahele o ka paipu e hoʻohana ana i ka pae-specific versus random conjugation, no laila e mālama i kēlā me kēia kiʻi me ka kānalua.

Pehea e wehewehe ʻia ai ka maʻemaʻe: peptide maemae, conjugate maemae, Puunaue DAR?

ʻAʻole hoʻokahi pākēneka HPLC kahi kikoʻī maʻemaʻe. ʻO ke alakaʻi alakaʻi synthetic-peptide EMA i hoʻomaka i Iune 2026 hoʻonoho iā Ph. Eur. nā paepae no nā haumia pili i ka peptide ma ka hōʻike ma luna 0.1%, hoʻomaopopo ma luna 0.5% a kūpono i luna 1.0%, koi i kekahi ano haumia e hoʻokō i ka 0.1% paepae hōʻike, a ʻaʻole ia e paipai i ka hui ʻana o nā haumia hiki ke hoʻokaʻawale ʻia (EMA/CHMP/CVMP/QWP/367182/2025, i ka hopena 2026-06-01). Mālama pū ʻo ia i ka maʻemaʻe e like me kekahi o nā CQA koʻikoʻi no nā peptides synthetic a koi i ka kikoʻī kikoʻī e hōʻike i ka huina a me nā haumia pilikino i kēlā mau paepae..

Nā paepae hoʻomalu haumia peptide Nā paepae hoʻomalu haumia peptide: waiwai no ka Hoike, E hoomaopopo, Kupono. Nā paepae hoʻomalu haumia peptide. ʻikepili lollipop: Hōʻike 0.1; E hoomaopopo 0.5; Pono 1.Source: EMA synthetic peptides alakaʻi 2025-12-04. Nā paepae hoʻomalu haumia peptide Hōʻike 0.1 E hoomaopopo 0.5 Kupono 1 Puna: EMA synthetic peptides alakaʻi (2025-12-04)

ʻO ke ala ma hope o ka helu he mau koi ponoʻī. I Q2(R2) Pono nā manaʻolana hōʻoia i ka maʻemaʻe a me ka haumia ʻano kikoʻī e hōʻike ʻia e kūʻē i nā laʻana spiked a koʻikoʻi paha a me kahi kaʻina orthogonal kahi hiki ʻole ke hoʻokaʻawale ʻia nā haumia. (I Q2(R2), 2023). Hoʻokahi hana HPLC, maikai nae ka holo ana, ʻaʻole ia he koi maʻemaʻe i hōʻoia ʻia.

He mea maoli nā papa haumia, ʻoiai ʻaʻole i paʻi ʻia nā alapine. A 2026 ʻike ʻia ka nānā ʻana i ka haumia o ka semaglutide synthetic 57 haumia maluna a 0.02% ʻoki ʻia ma waena o ʻeiwa mau mea lāʻau, me ka holoi ana o Thr, ʻO kāna a me Gly i waena o nā ʻano i ʻike ʻia (Kopp et al., ʻImi Lapaʻau, 2026). Kākoʻo ia i ka "holoi ʻia a pono e ʻimi ʻia"; ʻaʻole ia e kākoʻo i ka helu holoi ʻana.

He mea nui ka palena palena. Hoʻopuka ka alakaʻi alakaʻi EMA i nā moieties conjugation a me nā loulou e like me nā kumuhana CMC, me nā palapala hoʻolako a me ka loiloi mutagenic-impurity, ʻaʻohe mea e pili ana i nā ADC, uku pālua a i ʻole DAR. E hoʻohana iā ia no ka peptide, ʻaʻole no ka conjugate.

E wehewehe i ka peptide a me ka mea hoʻohui, nā haumia pili, ʻano conjugate, ka hoʻouka ʻana a me kēlā me kēia uku, uku uku a me ka paʻa no ka hana maoli. ʻAʻole ʻo SEC wale nō e hoʻokumu i ka maʻemaʻe conjugate holoʻokoʻa; hoʻohui i nā ʻano me ka uhi i hōʻike ʻia. ʻAʻole ʻokoʻa nā paepae Synthetic-peptide i nā palena ʻae ADC-linker.

He aha ka mea i loko o ka pūʻolo handoff analytical mai ka ʻike ʻana a hiki i ka hoʻomohala ʻana?

Pono ka pūʻolo handoff e ʻae i ka hui e loaʻa ana e hana hou i kāu mau helu me ka ʻole o ka hoʻomohala hou ʻana i nā assays. No nā ADC mau uku nui, pono e hoʻonui ʻia ka hoʻolālā bioanalytical ma mua o ka nui o ka antibody i ka conjugated-antibody assays, conjugated-payload LC-MS a intact-mass work, me ka nānā 'ana i waena no ka hā'awi 'ana i ka ukana lā'au (Riccardi Sirtori et al., ʻIkepili bioana, 2025). ʻO ka loiloi waena-lalo no ka hāʻawi ʻana i ka lawe ʻana i ka lāʻau lapaʻau ka ʻāpana i nalo pinepine ʻia mai kahi pūʻolo ʻike.

ʻOi aku ka haiki a ka mea hoʻolako peptide akā paʻa. Pehea e wehewehe ai ka mea hoʻolako linker-peptide i ka QC kūpono no ke kumu he HPLC a i ʻole UPLC maʻemaʻe me ka ʻike LC-MS, me ke koho pre- a me ka hōʻoia ʻana i ka cleavage post-trigger (Bio-Synthesis, nā mea hoʻopili peptide hiki ke wehe, kiʻi ʻia 2026-10). E noi i nā chromatograms kiko'ī nui a me nā kiko kikoʻī, ʻaʻole he hōʻuluʻulu palapala.

ʻElua mau āwaha pono. ʻAʻohe kumu e wehewehe i kahi ʻano hoʻoponopono i hoʻopaʻa ʻia no ke ana ʻana i kēlā me kēia uku uku o kēlā me kēia DAR i nā laʻana lapaʻau, ʻAʻole hiki i ka RPLC-UV hōʻemi ke hoʻoholo i nā koina DAR pākahi no kēlā me kēia uku no ka mea ua hui pū nā kaulahao kaumaha me ka huina DAR like ʻole akā hui pū nā hoʻonohonoho uku uku. (Nā lāʻau lapaʻau 19:860, 2026). Hāʻawi ka ʻōnaehana kikoʻī o ICH Q6B i nā loina maʻamau no ka hoʻonohonoho ʻana a me ka hōʻoia ʻana i nā kikoʻī no nā huahana olaola (FDA, Q6B, 1999), akā ʻaʻole haʻi ka framework iā ʻoe i ka assay e hoʻonā i kāu mau uku ʻelua.

Papa helu helu lima: kaʻina a me ka helu hailona; hoʻolālā pūʻulu pale a me ke kauoha deprotection; Hana HPLC/UPLC me ke kolamu, gradient a me ka lōʻihi nalu; ʻO ka ʻike LC-MS me ka ʻike ʻia me ka nui o ka manaʻo; papaʻaina haumia kūʻē 0.1/0.5/1.0%; hōʻoia hoʻokaʻawale inā hiki ke hoʻokaʻawale ʻia ka loulou; a me kahi ala i ʻōlelo ʻia no kēlā me kēia uku uku DAR, a i ʻole he palapala maopopo ʻaʻole i hoʻoholo ʻia.

Pehea ʻoe e koho ai ma waena o kahi loea maʻalahi a me kahi mea hoʻolako piha?

Huli ka koho i kahi e noho ai kāu kaohi. Hāʻawi kahi mea hoʻolako hoʻohui i hoʻokahi kuikahi ma waena o ka antibody, mea hoʻopili, uku hoʻopiha a hoʻopiha; Ua wehewehe ʻo Lonza i hoʻohui ʻia ʻo ADC hana hoʻohālike i ka hoʻoulu ʻana i ka uku uku gram-scale a me ka nui-kilogram ma Visp me kahi hāʻawi i hoʻohui ʻia ma waena o nā antibodies, mea hookui, nā ukana, bioconjugation a me ka hoʻopiha piha ʻana (Lonza, Nā Peptides Maʻemaʻe kiʻi ʻia 2026-10). ʻO kāna kumu hoʻohālike Advanced Synthesis kūpono i nā pae hiki ke loaʻa, hoʻomohala a me ka lako lapaʻau ma mua o ka hāʻawi ʻana i nā mea āpau i kēlā me kēia pae (Lonza media aʻoaʻo, 2026). Hale Hana Hana Peptide

Hoʻopili kekahi loea i hoʻokahi papa. He pōmaikaʻi kēlā inā he kaʻina ka pilikia paʻakikī: ʻelua mau cysteine ​​i pale ʻokoʻa, he polysarcosine spacer, he tag LPETG a i ʻole kahi holo hydrophobic e hōʻuluʻulu ʻia ma ka resin. He pōʻino ke makemake ʻoe i ka ʻōnaehana maikaʻi like e uhi i ka conjugation a me ka hoʻopiha-hoʻopau.

Kūlana

loea maʻalahi

Mea hoʻolako piha piha

Kūpono maikaʻi loa

Peptide paʻakikī a lālā paha, ʻano pale ʻokoʻa, kaʻina hana wikiwiki

Pono ka papahana i hoʻokahi ʻōnaehana maikaʻi mai ka loulou a hiki i ka hoʻopiha-hoʻopau

Hohonu hoʻonaʻauao Hana ʻia nā Peptides

HPLC/MS pae nui a me ka hōʻoia cleavage, ka hoʻomohala ʻana i ke ala no ka peptide

Hōʻike ʻo Platform ma waena o ka conjugate, ka ukana a me ka paʻa paʻa

pilikia hoʻonui

E hoʻoneʻe i kahi lua no ka conjugation a me ka lako lapaʻau

Hoʻoili kahua hoʻokahi, emi iho ka poho lima

Kahi e huli ai

ʻIke palekana Orthogonal, ʻO ke ʻano DAR pākahi uku, haumia hōʻike kūʻē 0.1%

Inā loaʻa i ka papa peptide ka hoʻomohala ʻano hoʻolaʻa a i ʻole ka pae paʻamau

ʻO ka hoʻohālikelike ʻana he kumu hoʻoponopono, ʻaʻole kahi kūlana kumu; ʻAʻohe kumu aʻu i nānā ai i nā pae hoʻohālike ʻelua i ke poʻo. E hoʻohana iā ia e kūkulu i nā nīnau, a laila e hoʻoholo nā pane.

Hōʻike

ʻElua mau hōʻailona kemika. ʻO nā kūlana cysteine ​​orthogonal mai 2017 a ua hōʻike ʻia ma kahi ʻano antibody, no laila he kuhikuhi hoʻolālā lākou, ʻaʻole he kaʻina hana i hōʻoia ʻia (Levengood et al., Angew Chem Int Ed, 2017). A ʻo ka ʻōlelo ʻana i ka DAR kiʻekiʻe ke kumu o ka hōʻuluʻulu ʻana he ʻokoʻa i kākau ʻia: ka 8+8 kūkulu ʻia i hiki 98% monomer me kahi kauā PEG24, no laila hydrophobicity masking, ʻaʻole ʻo DAR wale nō, ʻo ia ka hoʻololi. ʻAʻohe kumu e hāʻawi i kahi ana ʻana a i ʻole ka pohō maʻemaʻe no ka hoʻonui ʻana i kahi peptide paʻakikī i hoʻololi ʻia mai ka milligram a i ke kilo.; ʻO kēlā pilikia e noho qualitative.

Nīnau pinepine

Hiki i ka DAR kiʻekiʻe ke kumu i ka hui a me ka hoʻomaʻemaʻe wikiwiki?

ʻAʻole. Hoʻopili ʻia ka DAR kiʻekiʻe me ka hōʻuluʻulu a me ka hoʻomaʻemaʻe wikiwiki ʻana no nā uku hydrophobic, akā ua hoʻololi ʻia ka pilina e ka linker hydrophobicity (Ocana et al., ʻO ka hoʻololi ʻana i ka hōʻailona a me ka hoʻomaʻamaʻa ʻia, 2026). ʻO kahi kūkulu ʻelua-auristatin me kahi kikoo PEG24 i hōʻea 98% monomer (Levengood et al., Angew Chem Int Ed, 2017).

Ke uhi nei ke alakaʻi synthetic-peptide EMA i nā ADC pālua-uku?

ʻAʻole. Hoʻopili ia i nā peptides synthetic a mālama i nā moieties conjugation a me nā loulou e like me nā kumuhana CMC; ʻaʻohe mea e pili ana i nā ADC, uku pālua a i ʻole DAR (EMA/CHMP/CVMP/QWP/367182/2025, i ka hopena 2026-06-01).

Hiki i kahi loea peptide ke hāʻawi aku i kahi mea hoʻolako lapaʻau?

ʻAe, inā lawe ka pūʻolo lima i ka ʻikepili HPLC a me LC-MS, ka hoʻolālā pūʻulu pale a me ke kauoha deprotection, a me kahi ala i ʻōlelo ʻia no kēlā me kēia uku uku DAR. ʻO ke āpau e hoʻolālā ai, ʻaʻohe ala hoʻoponopono i hoʻopaʻa ʻia no kēlā me kēia uku DAR i nā hōʻailona lapaʻau i wehewehe ʻia i nā kumu i loiloi ʻia. (Nā lāʻau lapaʻau 19:860, 2026).

Ka hopena

ʻO ke kānāwai hoʻoholo no kahi hoa kākoʻo e hahai mai ia. E hoʻohālikelike i ka hoa pili i kāu kaohi maoli. Inā he lālā lālā a pale ʻokoʻa paha ke kaohi, ʻoi aku ka maikaʻi o kahi loea me ka ʻike pale orthogonal i hōʻike ʻia a me ka loiloi pae-nui. Inā he ʻōnaehana maikaʻi hoʻokahi ke kaohi ma waena o ka conjugation a me ka lako lapaʻau, lanakila ka mea hoʻolako i hoʻohui ʻia i ka pilikia hoʻoili. Ma na hihia elua, e noi i ka pūʻolo analytical ma mua o ka ʻōlelo, a mālama i ka mea hoʻolako ʻaʻole hiki ke wehewehe i kēlā me kēia uku uku DAR ma ke ʻano he mea hoʻolako ʻaʻole i hoʻoponopono i ka hapalua analytical o ka pilikia.

ʻO ka ʻanuʻu aʻe he loiloi loea o kāu kaʻina a me kāu kikoʻī: papahana pūʻulu pale, kauoha deprotection, nā paepae haumia a me ke ʻano DAR, palapala ʻia e kūʻē i ka mea hiki i kahi hoa kākoʻo ke palapala hailona ma ka hailona.

Hōʻike ka mea hoʻopuka: Hāʻawi ʻo MOL Changes i nā lawelawe peptide a he hoihoi koʻikoʻi i kēia kumuhana. ʻO nā lālā lawelawe a me nā ʻōlelo hiki ke koi i nā mea hoʻolako; ʻO ka loaʻa a me ka hana ʻana no kahi kūkulu kikoʻī e koi i nā hōʻike kikoʻī o ka papahana.

Jinling Liu

Jinling Liu

Kaʻina hana R&D a me ka Mea Hana Hana Kaʻike kumu: Hoʻonui kaʻina hana, kemika ʻōmaʻomaʻo, hoʻomaikaʻi maikaʻi, Hoʻokō ka hana GMP.

Pilikino: He loea ʻo Jinling Liu i ka unuhi ʻana o nā lāʻau peptide mai ka pālākiō keʻena (pae milligram) i ka hana pāʻoihana (pae kilokani). Ua kūpaʻa ʻo ia i ka hōʻemi nui ʻana i nā kumukūʻai hana peptide a me ka hōʻemi ʻana i ka pollution kaiapuni ma o ka hoʻonui ʻana i nā kūlana cleavage., ka hoʻomaikaʻi ʻana i nā lakio o nā condensation reagents, a me ka hoʻolauna ʻana i ka ʻenehana synthesis kahe mau. Ua alakaʻi ʻo ia i ka optimization o nā papahana peptide he nui, ka loaʻa ʻana o ke kumu kūʻai haʻahaʻa, hoʻomaʻemaʻe kiʻekiʻe ma ka pālākiō 100-kilogram.

ʻIke ʻia & Nā alakaʻi hoʻoponopono
Nānā ʻia e: Ka poe akamai kumuhana
Kaʻana like i kēia ʻatikala
Home Huli Whatsapp Nā lawelawe Huahana